Sign Out
The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets is not recommended during pregnancy. The safety of abacavir and lamivudine in human pregnancy has not been established. Studies with abacavir and lamivudine in animals have shown reproductive toxicity.
It is recommended that HIV-infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV. Lamivudine is excreted in human milk at similar concentrations to those found in serum. It is expected that abacavir will also be secreted into human milk, although this has not been confirmed. It is therefore recommended that mothers do not breast-feed their babies while receiving treatment with the fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets.
Continue with Google